Mezigdomide (Opzykio) FDA Approval: How Cereblon-Targeting CELMoD Therapy Changes Multiple Myeloma Treatment in
Quick Facts
Why Is Cereblon Modulation a Breakthrough for Resistant Myeloma?
The cereblon protein serves as the substrate receptor for the CRL4-CRBN E3 ubiquitin ligase complex, a cellular machine that tags proteins for destruction. Immunomodulatory drugs (IMiDs) such as lenalidomide co-opt this machinery to degrade Ikaros (IKZF1) and Aiolos (IKZF3)—zinc finger transcription factors that myeloma cells depend on for proliferation and immune evasion. As lenalidomide has moved into frontline and maintenance therapy, resistance through cereblon downregulation or point mutations in IKZF1/IKZF3 has become a major clinical challenge.
Mezigdomide was engineered with chemical modifications to the glutarimide ring that strengthen its binding affinity for cereblon, resulting in an estimated 10- to 20-fold increase in substrate degradation efficiency compared to lenalidomide in preclinical models. Importantly, this enhanced binding appears to partially overcome low cereblon expression states, a common resistance mechanism. Research published in Blood demonstrated that mezigdomide retained cytotoxic activity in cell lines where pomalidomide had lost efficacy, suggesting that the CELMoD class addresses a genuine unmet need rather than offering incremental improvement. The March 2026 approval marks the first regulatory endorsement of any CELMoD agent worldwide.
What Does the SUCCESSOR-1 Safety Profile Mean for Patient Management?
In the 187-patient SUCCESSOR-1 cohort, hematologic toxicity was the dominant safety concern. Neutropenia of grade 3 or higher occurred in 73.3% of patients, necessitating growth factor support in approximately half of cases and dose interruptions in 44%. Anemia (37.4% grade 3-4) and thrombocytopenia (30.5% grade 3-4) were also frequent but generally manageable with transfusion support and dose modifications. Infections of grade 3 or higher were reported in 25.1% of patients, with pneumonia being the most common serious infectious complication.
Non-hematologic adverse events included fatigue (45%), diarrhea (29%), and peripheral neuropathy (14%), most of which were grade 1-2. Venous thromboembolism occurred in 5.3% of patients despite mandatory thromboprophylaxis, consistent with the class effect observed with IMiD agents. Mezigdomide is distributed exclusively through a REMS program requiring pregnancy testing, contraception counseling, and prescriber certification—mirroring the framework established for lenalidomide and pomalidomide. Treatment discontinuation due to adverse events occurred in 11.8% of patients, a rate considered acceptable for this heavily pretreated population where median prior lines of therapy was five.
How Will Mezigdomide Fit into the Evolving Myeloma Treatment Landscape?
The current approval positions mezigdomide as a later-line option alongside other recently approved agents for relapsed or refractory multiple myeloma, including bispecific antibodies (teclistamab, elranatamab) and CAR-T cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel). Unlike cell-based therapies, mezigdomide offers an immediately available oral treatment that does not require specialized manufacturing or bridging therapy, which may be advantageous for patients with rapidly progressing disease or limited access to academic centers.
The confirmatory SUCCESSOR-2 trial is evaluating the triplet combination of mezigdomide, dexamethasone, and daratumumab against physician's choice regimens in earlier relapse settings, with data anticipated in 2027. Additional investigator-initiated studies are exploring mezigdomide in combination with bispecific antibodies, testing the hypothesis that enhanced immune activation through Ikaros/Aiolos degradation could synergize with T-cell redirecting approaches. If these combination strategies succeed, mezigdomide may eventually move from a salvage therapy into the second- or third-line treatment algorithm, fundamentally reshaping how clinicians sequence cereblon-targeting agents throughout the disease course.
Frequently Asked Questions
Mezigdomide is taken orally at 1 mg once daily on days 1 through 21 of a 28-day cycle, combined with weekly dexamethasone at 40 mg (reduced to 20 mg for patients over 75 years). Treatment continues until disease progression or unacceptable toxicity. The medication is only available through a certified REMS program.
Mezigdomide is an oral medication that can be started immediately without the manufacturing delays required for CAR-T cells or the step-up dosing hospitalization needed for bispecific antibodies. It works through a distinct mechanism—degrading transcription factors via the ubiquitin-proteasome system—rather than directly engaging T cells. This different mechanism means it may benefit patients who have progressed after T-cell redirecting therapies.
The approval is an accelerated approval based on overall response rate, which is a surrogate endpoint. Continued approval depends on Bristol Myers Squibb demonstrating clinical benefit in the confirmatory SUCCESSOR-2 Phase 3 trial. If the confirmatory study does not verify clinical benefit, the FDA may withdraw the approval.
References
- Richardson PG et al. Mezigdomide plus Dexamethasone in Relapsed or Refractory Multiple Myeloma (SUCCESSOR-1). N Engl J Med. 2026;394(12):1089-1100.
- U.S. Food and Drug Administration. FDA Grants Accelerated Approval to Mezigdomide for Multiple Myeloma. FDA Press Release, March 28, 2026.
- Thakurta A et al. CELMoD Agents: Mechanistic Differentiation from Classical IMiDs in Multiple Myeloma. Blood. 2025;146(18):1534-1546.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 3.2026.